李登瑞,杨永辉,李辉,李秀武,郭素敏,任雪飞,刘晓鹏,高莉

• 1:河北省胸科医院结核科河北省肺癌防治中心
• 2:河北省胸科医院病理科河北省肺癌防治中心
• 3:河北省胸科医院胸外科河北省肺癌防治中心
• 4:河北省胸科医院生物治疗科河北省肺癌防治中心

摘要(Abstract)：

目的探讨异基因半相合细胞因子诱导的杀伤细胞(cytokine induced killer cell,CIK)治疗晚期非小细胞肺癌的临床疗效。方法 25例晚期非小细胞肺癌患者接受CIK细胞治疗。采用患者子女的外周血(异基因半相合)分离单个核细胞置于CD3 Mc Ab和Retro-Nectin包被细胞培养瓶后,悬浮细胞用干扰素-γ、白介素-1α(interleukin-1α,IL-1α)、IL-2细胞因子诱导CIK细胞。14天后锥虫蓝染色检测活性,流式细胞仪检测CIK细胞表面标志物。患者回输CIK细胞后,检测患者外周血的细胞表型变化。参照WHO的实体瘤疗效评价标准评估疗效。结果 CIK细胞培养到第14天时为10.7×109个,锥虫蓝染色检测活性为(98.2±1.0)%。流式细胞仪检测到CD56+CD16+CD3+细胞较培养前显著增加[(30.2±1.5)%vs(6.0±2.0)%,P<0.05]。患者回输后外周血CIK细胞第10天、第20天较回输前显著增加(P<0.05)。CIK细胞回输后临床评估CR 10例,PR 8例,NC 5例,PD 2例,总有效率(CR+PR)为72.0%,中位缓解期为10.1月,中位生存期为12.0月,1年生存率为64.0%(16/25)。患者无骨髓抑制、脱发、静脉炎和消化道反应。结论异基因半相合CIK细胞治疗晚期非小细胞肺癌能延长患者生存期,提高生存质量,不良反应轻。

关键词(KeyWords)： 癌,非小细胞肺;肺肿瘤;杀伤细胞/药物作用;治疗结果

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(31101638);; 2013年河北省省级重大医学研究课题(ZD2013063;ZD2013060);; 2014年河北省省级科技计划项目(14277789D)

作者(Author): 李登瑞,杨永辉,李辉,李秀武,郭素敏,任雪飞,刘晓鹏,高莉

DOI: 10.13267/j.cnki.syzlzz.2015.06.026

参考文献(References)：

• [1]Park DI,Kim SY,Kim JO,et al.The prognostic value of the tumor shrinkage rate for progression-free survival in patients withnon-small cell lung cancer receiving gefitinib[J].Tuberc Respir Dis(Seoul),2015,78(4):315-320.
• [2]Rong X,Wei F,Li A,et al.Effective activity of cytokine induced killer cells against hepatocellular carcinoma including tumor-initiating cells[J].Med Hypotheses,2015,84(3):159-161.
• [3]Schmidt-Wolf IS,Finke S,Trojaneck B,et al.Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic crenal cancer,colorectal cancer and lymphoma[J].Br J Cancer,1999,81(6):1009-1016.
• [4]Youlin K,Jian K,Siming L,et al.Potent anti-prostate cancer immune response induced by dendritic cells transduced with recombinant adenoviruses encoding 4-1BBL combined with cytokine-induced killer cells[J].Immunotherapy,2015,7(1):13-20.
• [5]Stone KB,Oddis CV,Fertig N,et al.Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy[J].Arthritis Rheum,2007,56(9):3125-3131.
• [6]WHO.WHO handbook for reporting results of cancer treatment[M].London:WHO Publication,1979:45.
• [7]Wang W,Qin S,Zhao L.Docetaxel enhances CD3+CD56+cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation[J].Biomed Pharmacother,2015,69:18-23.
• [8]Chung MJ,Park JY,Bang S,et al.PhaseⅡclinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer[J].Cancer Immunol Immunother,2014,63(9):939-946.
• [9]Schmidt TL,Negrin RS,Contag CH.A killer choice for cancer immunotherapy[J].Immunol Res,2014,58(2-3):300-306.
• [10]Li DP,Li W,Feng J,et al.Adjuvant chemotherapy with sequential cytokine-induced killer(CIK)cells in stage IB non-small cell lung cancer[J].Oncol Res,2015,22(2):67-74.
• [11]Tao Q,Chen T,Tao L,et al.IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+cells and downregulating regulatory T cells as well as IL-35[J].J Immunother,2013,36(9):462-467.
• [12]Introna M,Golay J,Rambaldi A.Cytokine Induced Killer(CIK)cells for the treatment of haematological neoplasms[J].Immunol Lett,2013,155(1-2):27-30.
• [13]Li W,Wang Y,Zhao L,et al.Efficacy of retronectinactivated cytokine-induced killer cell therapy in metastatic brain tumor patients[J].Oncol Res Treat,2015,38(4):160-165.
• [14]Wang S,Zhang H,Liu C,et al.Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer[J].Oncol Lett,2014,8(6):2727-2733.
• [15]王丹红,高海燕,张斌,等.DC-CIK治疗晚期非小细胞肺癌的近期临床疗效观察[J].实用肿瘤杂志,2013,28(4):378-381.
• [16]和钢,杨峂,张顺.自体CIK回输对转移性恶性肿瘤细胞免疫指标变化的影响[J].实用肿瘤杂志,2014,29(5):45-48.